Looking for Kinetico Water Systems? Click Here!

Contract Research Organization Insights Kineticos is Your Source for Trusted CRO Knowledge

Through a dedication to continuing education, Kineticos’ life science experts deliver an up-to-date understanding of current trends related to CROs and CRO labs. Explore the case studies, white papers, and articles below to find knowledge and discussion pertaining to cutting-edge issues for contract manufacturing organizations.

Click the Tabs Below for CRO Case Studies, White Papers & Articles, and Blog

 


Case Studies
Articles
Blog
  • The Disruptor26 Podcast Series with Paul Garofolo

    Locus Biosciences is revolutionizing the treatment of bacterial disease using its CRISPR-Cas3 technology to kill targeted bacteria while leaving the many species of good bacteria in the body unharmed. Listen to Kineticos Founder and CEO Shailesh Maingi and Paul Garofolo, CEO of Locus Biosciences as they discuss the past, present, and future of Locus Biosciences … Continue reading The Disruptor26 Podcast Series with Paul Garofolo »

     

    Read this Article

  • 2020 Q1 BCI – Fundamentals of Running a Biopharmaceutical

    The Biopharma CEO Confidence Index is a forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry’s economy. The BCI measures c-suite and executive leadership sentiment in the biopharma industry asking questions about their confidence levels concerning key issues. We look for the BCI to become a valuable and highly sought-after resource for … Continue reading 2020 Q1 BCI – Fundamentals of Running a Biopharmaceutical »

     

    Read this Article

  • What Can China Teach Us About CAR-T?

    What Can China Teach Us About CAR T is the final installment of our CAR-T series and discusses how China has embraced CAR-T therapy.  Our panelists also touch on how China and the US can grow off of each other’s strengths. Moderator Shailesh Maingi, Founder and CEO, Kineticos Panel Members Bill Farley, VP of Business … Continue reading What Can China Teach Us About CAR-T? »

     

    Read this Article

  • Staying the Course

    Written by Mark Osterman, Senior Vice President, Kineticos Kineticos recently announced Q4 2015 results of the Biopharma CEO Confidence Index, which showed a tempering of enthusiasm among biopharma CEOs compared to the Q3 2015 study. The results of the Q4 index, which is intended to serve as an indicator of CEO sentiment in the biopharma … Continue reading Staying the Course »

     

    Read this Article

  • Cell and Gene Therapies: The Path to Commercialization

      Regenerative Medicine holds enormous potential for treating and ameliorating many chronic conditions for which we do not yet have viable treatment options, with the potential to address ever-increasing medical costs and improve the quality of life of countless sufferers and their families. However, the challenges associated with developing and delivering these therapies are daunting, … Continue reading Cell and Gene Therapies: The Path to Commercialization »

     

    Read this Article

  • Bridges and Barriers to Advancing CAR T Therapy

    One result of the Oncology explosion over the past 10 years has been the advent of CAR T therapy. In fact, we have seen two recent approvals, both for hematological cancers. Yet, the industry has not made nearly as much progress in solid tumors. Kineticos’ Operating Executive, Steve Buckanavage, recently caught up with Dr. Jeffrey Skolnik, VP … Continue reading Bridges and Barriers to Advancing CAR T Therapy »

     

    Read this Article

  • Growth by Acquisition in Life Sciences: Do You Have a Plan?

      As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as Roche’s acquisition of Ariosa Diagnostics and LabCorp’s acquisition of Covance, bring to light an important question for decision makers in the life sciences industry: When it comes to growth by acquisition, what is your plan? … Continue reading Growth by Acquisition in Life Sciences: Do You Have a Plan? »

     

    Read this Blog Post

  • R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation

    James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?

     

    Read this Blog Post

  • Merck KGaA and Bayer Choose Opposite Strategies

      Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent blogs, Merck KGaA and Bayer are both responding to the basic core of their original strategies—Merck KGaA is acquiring Sigma-Aldrich to diversify their materials and services and Bayer is “spinning-off” (and eventually selling, over the … Continue reading Merck KGaA and Bayer Choose Opposite Strategies »

     

    Read this Blog Post

  • Foundation Medicine and Clovis Expand Partnership

      In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion diagnostic for a Clovis drug currently in clinical trials.1 Specifically, the test is being developed in conjunction with the FDA new drug application submission for Rucaparib, a polymerase inhibitor for the treatment of…

     

    Read this Blog Post

  • Role of Companion Diagnostics in Immuno-oncology Race Unfolding

      Important oncology events, including ASCO and ESMO, have recently displayed the fruits of the huge investment drug companies have put into oncology, especially the immuno-oncology therapies centered on PD-1. In previous blogs, I noted that BMS appeared to be leaning toward not incorporating a companion diagnostic for nivolumab (another anti-PD-1 therapy) in melanoma … Continue reading Role of Companion Diagnostics in Immuno-oncology Race Unfolding »

     

    Read this Blog Post

  • Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity

      As reported by Bloomberg and the Wall Street Journal, Bayer is expected to announce plans to sell its plastics unit, creating a key shift from chemicals to the life science industry. Along with Merck KGaA, Bayer is one of Europe’s last foremost drug and chemical multinationals, making the shift unprecedented, if not unexpected. … Continue reading Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity »

     

    Read this Blog Post

Subscribe to our internal think tank, Kineticos Research Institute